Knight Therapeutics Inc. (TSE:GUD - Get Free Report)'s stock price shot up 9.2% during mid-day trading on Tuesday . The company traded as high as C$6.04 and last traded at C$5.95. 215,326 shares were traded during trading, an increase of 313% from the average session volume of 52,166 shares. The stock had previously closed at C$5.45.
Analysts Set New Price Targets
Separately, Raymond James upgraded shares of Knight Therapeutics to a "moderate buy" rating in a research note on Friday, November 15th.
Read Our Latest Report on Knight Therapeutics
Knight Therapeutics Stock Performance
The business's fifty day simple moving average is C$5.58 and its 200-day simple moving average is C$5.56. The company has a market capitalization of C$606.90 million, a P/E ratio of -20.03, a P/E/G ratio of -1,013.50 and a beta of 0.50. The company has a debt-to-equity ratio of 7.52, a quick ratio of 1.79 and a current ratio of 3.36.
Insider Activity at Knight Therapeutics
In other Knight Therapeutics news, insider Sime Armoyan bought 17,600 shares of the business's stock in a transaction dated Tuesday, March 4th. The shares were purchased at an average price of C$5.48 per share, with a total value of C$96,488.48. 45.62% of the stock is currently owned by insiders.
Knight Therapeutics Company Profile
(
Get Free Report)
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
Further Reading
Before you consider Knight Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Knight Therapeutics wasn't on the list.
While Knight Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
